VICTORIA — October 27, 2025 Leads & Copy — Aurinia Pharmaceuticals Inc. (TSX:AUP, Nasdaq:AUPH) rose 6.8 percent this month after posting stronger Q3 sales of its lupus nephritis drug, Lupkynis, and announcing a cost-reduction plan to improve operating margins.
The Victoria-based firm said Lupkynis revenue grew 18 percent year-over-year, driven by broader adoption among U.S. specialists and expanded insurance coverage. Aurinia plans to trim operating expenses by 12 percent in 2026 through workforce and vendor consolidation.
CEO Peter Greenleaf said the company remains focused on maximizing Lupkynis market share while advancing its autoimmune pipeline, including a Phase 2 candidate for Sjögren’s syndrome.
Aurinia shares have rebounded 21 percent since July, reversing earlier losses tied to reimbursement delays.
